Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Man Xu

Showing results (731-740 of 739) with videos related to

Pageof 74
Sort By:
You have reached the last page of results.This site can display upto 739 results.
Cancer Cell|September 12, 2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASShunsuke Kitajima, Hajime Asahina, Ting Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Cancer Research|September 22, 2021
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXdHeidi M Haikala, Timothy Lopez, Jens Köhler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
BMJ (Clinical Research Ed.)|March 20, 2026
Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trialXinmiao Zhang, Lingling Ding, Jing Jing, et al.
Molecular Cancer|July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitorsJordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Pageof 74

Showing results (731-740 of 739) with videos related to

Sort By:
Pageof 74
You have reached the last page of results.This site can display upto 739 results.
Cancer Cell|September 12, 2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASShunsuke Kitajima, Hajime Asahina, Ting Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung CancerElena Ivanova, Mari Kuraguchi, Man Xu, et al.
Cancer Research|September 22, 2021
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXdHeidi M Haikala, Timothy Lopez, Jens Köhler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
BMJ (Clinical Research Ed.)|March 20, 2026
Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trialXinmiao Zhang, Lingling Ding, Jing Jing, et al.
Molecular Cancer|July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitorsJordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
JCI Insight|January 23, 2026
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapyAtsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, et al.
Science Translational Medicine|September 13, 2021
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i>-mutant lung cancerPınar Özden Eser, Raymond M Paranal, Jieun Son, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Pageof 74